Why the study?
Do genetic polymorphisms in VKORC1, CYP2C9, CYP4F2, and GGCX affect warfarin maintenance dose and plasma concentration in Chinese patients with cardiac valve replacement?
Do genetic polymorphisms in VKORC1, CYP2C9, CYP4F2, and GGCX affect warfarin maintenance dose and plasma concentration in Chinese patients with cardiac valve replacement?
Genetic variants in VKORC1 and CYP2C9 significantly influence warfarin maintenance dose and plasma concentration requirements in Chinese patients, supporting the use of pharmacogenetic-based dosing algorithms.
No takes yet. Share an insight, caveat, or question.
Supports pharmacogenetic dosing models in Chinese valve patients; leaves open outcome benefits without RCTs.
Li et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: